Synlogic, Inc. announced the appointment of Michael Burgess, M.B., Ch.B., Ph.D., president of research and development at Turnstone Biologics, to its board of directors. Dr. Mike Burgess is a recognized senior leader in the pharmaceutical industry with 20 years of drug research and development experience. He has served as President of Research and Development at Turnstone Biologics, a clinical stage viral immunotherapy cancer company, since 2017.